
    
      A special drug use surveillance is planned to examine the safety and efficacy of long-term
      use of alogliptin in patients with type 2 diabetes mellitus under the daily clinical use
      conditions.

      Participants of this surveillance will be patients with type 2 diabetes mellitus who failed
      to respond adequately to diet therapy and exercise therapy alone or to a combination of diet
      therapy, exercise therapy, and Î±-glucosidase inhibitor. The planned sample size is 3,000
      subjects.

      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily. Participants
      will receive the drug as part of routine medical care.
    
  